NASDAQ:STAA - STAAR Surgical Stock Price, Price Target & More

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical (NASDAQ:STAA) posted its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.08. The medical instruments supplier had revenue of $27.09 million for the quarter, compared to analyst estimates of $23 million. STAAR Surgical had a return on equity of 6.80% and a net margin of 0.66%. During the same period last year, the company earned ($0.05) earnings per share. View STAAR Surgical's Earnings History.

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for STAAR Surgical.

4 Wall Street analysts have issued twelve-month price targets for STAAR Surgical's shares. Their predictions range from $21.00 to $32.00. On average, they anticipate STAAR Surgical's share price to reach $24.6667 in the next twelve months. This suggests that the stock has a possible downside of 27.2%. View Analyst Ratings for STAAR Surgical.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to STAAR Surgical include Integra Lifesciences (IART), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), DiaSorin (DSRLF), Envision Healthcare (EVHC), United Therapeutics (UTHR), Aurora Cannabis (ACB), Loxo Oncology (LOXO), STADA Arzneimittel (SAZ), GALAPAGOS NV/S (GLPG), Masimo (MASI), Agios Pharmaceuticals (AGIO), Chemed (CHE), Medidata Solutions (MDSO) and Globus Medical (GMED).

Media headlines about STAA stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. STAAR Surgical earned a news sentiment score of 0.04 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 48.56 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

STAAR Surgical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (2.78%), Columbia Partners L L C Investment Management (0.27%) and Fred Alger Management Inc. (0.08%). Company insiders that own STAAR Surgical stock include Caren L Mason, Deborah J Andrews, Hans-Martin Blickensdoerfer, Keith Holliday and Samuel J Gesten. View Institutional Ownership Trends for STAAR Surgical.

STAA stock was acquired by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management, Baillie Gifford & Co. and Fred Alger Management Inc.. View Insider Buying and Selling for STAAR Surgical.

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of STAA stock can currently be purchased for approximately $33.90.

STAAR Surgical has a market capitalization of $1.41 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]